Nevertheless, the molecular mechanisms underlying MELK function in promoting cancer progression remain poorly understood, at least in prostate cancer, and so far, although we have found MELK to be consistently upregulated across multiple prostate cancer datasets (Fig EV2E), only two publications have reported a potential role in prostate cancer (Kuner et al, 2013; Ross‐Adams et al, 2015). Here, MELK is linked to prostate carcinoma.